The potential role for lixivaptan in heart failure and in hyponatremia

Expert Opinion on Investigational Drugs

Volumn 20, Issue 6, 2011, Pages 831-848

  Zmily, Hammam D ^a   Khan, Nazia S ^a   Daifallah, Suleiman ^b   Ghali, Jalal K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

arginine vasopressin antagonist; heart failure; lixivaptan

Indexed keywords

ARGIPRESSIN; FUROSEMIDE; LIXIVAPTAN; VASOPRESSIN V2 RECEPTOR;

ARTICLE; ASPIRATION PNEUMONIA; BACTERIAL PERITONITIS; BRAIN DISEASE; CLINICAL TRIAL (TOPIC); DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; FLATULENCE; HEADACHE; HEART FAILURE; HEPATORENAL SYNDROME; HUMAN; HYPERVOLEMIA; HYPONATREMIA; NONHUMAN; PATHOPHYSIOLOGY; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PREVALENCE; SINGLE DRUG DOSE; UMBILICAL HERNIA; UMBILICAL HERNIA RUPTURE; UPPER GASTROINTESTINAL BLEEDING; XEROSTOMIA;

ANIMALS; ARGININE VASOPRESSIN; BENZAMIDES; HEART FAILURE; HUMANS; HYPONATREMIA; PLASMA VOLUME; PYRROLES; RECEPTORS, VASOPRESSIN;

EID: 79955814237     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.579102     Document Type: Article

References (63)

1. Carnethon M, Rosamond W, Furie K, et al. American heart association statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2010 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2010;121:e46-215
2. Ghali JK, Tam SW. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. J Card Fail 2010;16:419-31
3. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009;122:857-65
4. Wald R, Jaber BL, Price LL, et al. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010;170:294-302
5. Sajadieh A, Binici Z, Mouridsen MR, et al. Mild hyponatremia carries a poor prognosis in community subjects. Am J Med 2009;122:679-86
6. Ghali JK, Vaitkevicius P. Fluid removal: are we any wiser? J Card Fail 2008;14:6-8
7. Ghali JK. Mechanisms, risks, and new treatment options for hyponatremia. Cardiology 2008;111:147-57
8. Wang W, Zucker IH. Cardiac sympathetic afferent reflex in dogs with congestive heart failure. Am J Physiol 1996;271:R751-6
9. Decaux G. Is asymptomatic hyponatremia really asymptomatic? Am J Med 2006;119(7A):S79-82
10. Renneboog B, Vendemergel X, Manto MN, et al. Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits. Am J Med 2006;119:71e1-8
11. Share L. Role of vasopressin in cardiovascular regulation. Physiol Rev 1988;4:1248-84
12. Kamoi K, Ishibashi M, Yamaji T. Interaction of osmotic and nonosmotic stimuli in regulation of vasopressin secretion in hypoosmolar state of man. Endocr J 1997;44:311-17 (Pubitemid 27229877)
13. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064-72 (Pubitemid 46789896)
14. Goldsmith SR, Francis GS, Cowley AW. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 1986;58:295-9 (Pubitemid 16052721)
15. Pruszczynski W, Vahanian A, Ardaillou R, et al. Role of antidiuretic hormone in impaired water excretion of patients with congestive heart failure. J Clin Endocrinol Metab 1984;58:599-605 (Pubitemid 14137249)
16. Bichet DG, Kortas C, Mettauer B, et al. Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int 1986;29:1188-96 (Pubitemid 16094232)
17. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9 (Pubitemid 20367975)
18. Schrier RW. Water and sodium retention in edematous disorder: role of vasopressin and aldosterone. Am J Med 2006;119:S47-53
19. Suzuki S, Takeshita A, Imaizumi T, et al. Biphasic forearm vascular responses to intraarterial arginine vasopressin. J Clin Invest 1989;84:427-34 (Pubitemid 19196972)
20. Coyle S, Penney MD, Masters PW, et al. Early diagnosis of ectopic arginine vasopressin secretion. Clin Chem 1993;39:152-4 (Pubitemid 23034978)
21. Thibonnier M, Conarty DM, Preston JA, et al. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998;449:251-76 (Pubitemid 28566397)
22. Ali F, Guglin M, Vaitkevicius P, et al. Therapeutic potential of vasopressin receptor antagonists. Drugs 2007;67:847-58 (Pubitemid 46607386)
23. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1A and V2 receptor-mediated effects. Cardiovasc Res 2001;51:372-90 (Pubitemid 32718586)
24. Goldsmith SR. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am J Cardiol 2005;95:14B-23B (Pubitemid 40545928)
25. Hirano T, Yamamura Y, Nakamura S, et al. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000;292:288-94 (Pubitemid 30026383)
26. Miller PD, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity: correlation in hyponatremic cirrhotic patients. JAMA 1980;243:2513-15 (Pubitemid 10039244)
27. Jackson EK. Diuretics. Hardman JG, Limbird LE. editors, Goodman and Gilman's the pharmacological basis of therapeutics. 9th edition. McGraw-Hill; New York: 1996. p. 757-88
28. Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992;105:787-91
29. Serradeil-Le Gal C, Lacour C, Valette G, et al. Characterization of SR 121463A, a highly potent and selective orally active vasopressin V2 receptor antagonist. J Clin Invest 1996;98:2729-38 (Pubitemid 26427399)
30. Tahara A, Tomura Y, Wada KI, et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 1997;282:301-8 (Pubitemid 27425555)
31. Chan PS, Couplet J, Park HC, et al. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol 1998;449:439-43 (Pubitemid 28566418)
32. Albright JD, Reich MF, Delos Santos EG, et al. 5-Fluoro-2-methyl-N-[4- (5H-pyrrolo [2,1-c]-[1, 4] benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl] benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem 1998;41:2442-4 (Pubitemid 28321894)
33. Park CH, Lock YW, Tanikella TK, et al. In vitro pharmacology of VPA-985, a non-peptide V2 selective vasopressin antagonist. J Am Soc Nephrol 1998;9:A0120
34. Chan PS, Lai F, Ru X, et al. Pharmacological characterization of VPA-985, a potent nonpeptidic orally-active and selective vasopressin (AVP) V2 receptor antagonist. J Am Soc Nephrol 1998;9:A0081
35. Muralidharan G, Meng X, DeCleene SA, et al. Pharmacokinetics and pharmacodynamics of a novel vasopressin receptor antagonist, VPA-985, in healthy subjects. Clin Pharmacol Ther 1999;65(2):189
36. Guyader D, Patat A, Ellis-Grosse EJ, et al. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002;36(5):1197-205 (Pubitemid 35253436)
37. Ellis-Grosse EJ, Meng X, Orczyk GP. Single dose pharmacokinetic (PK)-pharmacodynamic (PD) profile of VPA-985, a novel, V2 receptor antagonist, in patients with congestive heart failure (CHF) [abstract]. AAPS PharmSci 1999;1:S1
38. Orlandi C, Ticho B. The effect on renal function of lixivaptan (VPA-985), a vasopressin V2 receptor antagonist, in combination with furosemide [abstract 618]. Eur J Heart Fail 2009;8:2
39. Swan SK, Lambrecht LJ, Orczyk GP, et al. Interaction between VPA-985, an ADH (V2) antagonist, and furosemide. J Am Soc Nephrol 1999;10:124A
40. Epstein M, Orczyk G, Muralidharan G, et al. VPA-985: A novel non-peptide competitive vasopressin receptor antagonist for the treatment of dilutional hyponatremia. J Am Soc Nephrol 1998;9:abstract A0544
41. Swan SK, Anjum S, Lambrecht LJ, et al. Pharmacodynamic effects of VPA-985, an ADH (V2) antagonist, in normal volunteers. J Am Soc Nephrol 1999;10:124A
42. Abraham W, Ghali J, Braman V, et al. Effects of single dose administration of lixivaptan, a selective V2 receptor antagonist, or furosemide in healthy volunteers [abstract 1064]. Eur J Heart Fail 2010;9:1
43. Patat A, Ellis Grosse EJ, Orczyk G, et al. Pharmacodynamic (PD) effects of a novel, non-peptide, V2 receptor antagonist, VPA-985 (VPA), given with hydrochlorothiazide (H) [abstract PI-84]. Clin Pharmacol Ther 2000;67:2
44. Radin J, McCune S, Park S, et al. Effect of chronic administration of the vasopressin V2 receptor antagonist lixivaptan (VPA-985) on renal and cardiovascular functions in a rat model of heart failure [abstract 620]. Eur J Heart Fail 2009;8:2
45. Abraham WT, Shamshirsaz AA, McFann K, et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006;47:1615-21
46. Martin PY, Abraham WT, Lieming X, et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 1999;10(10):2165-70 (Pubitemid 29453494)
47. CardioKine, Inc. Study to evaluate the effects of oral administration of lixivaptan in patients with congestive heart failure. Clinicaltrials.gov NCT01055912. Available from: http:// clinicaltrials.gov/ct2/show/NCT01055912
48. CardioKine, Inc. The BALANCE study: treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation. Clinicaltrials.gov. NCT00578695. Available from: http:// clinicaltrials.gov/ct2/show/NCT00578695
49. Wong F, Blei AT, Blendis LM, et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Curr Mol Med 2003;37(1):182-91 (Pubitemid 36042159)
50. Wong F, Blei AT, Blendis M, et al. The efffects of VPA-985, a vasopressin receptor antagonist on water metabolism in patients with hyponatremia: a multi-center randomized placebo controlled trial [abstract 1094]. Gastroenterology 2000;118:Suppl 2):4
51. Gerbes AL, Golberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124(4):933-9 (Pubitemid 36389796)
52. Gross P, Decaux G, Gerbes A, et al. Treatment of hyponatremia (HYPO) with VPA-985. J Am Soc Nephrol 1999;10:121A
53. Gerbes AL, Guelberg V, Decaux G, et al. VPA-985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double-blind placebo controlled multicenter trial. Hepatology 1999;30(4 Pt 2):419A
54. Decaux G, Hannotier P, Pennickx R, et al. Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non-peptide, oral active selective vasopressin V2 receptor antagonist, VPA-985. J Am Soc Nephrol 1999;10:120A
55. Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 2001;138(1):18-21 (Pubitemid 32589198)
56. Bichet DG, Remillard G, Madore F, et al. Correction of hyponatremia by a single oral dose of 75 mg of the non-peptide vasopressin V2 antagonist VPA-985 in hyponatremic patients receiving carbamazepine (CBZ) (Tegretol) or oxcarbazepine (OBZ) (Trileptal). J Am Soc Nephrol 1999;10:119A
57. CardioKine, Inc. Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral lixivaptan capsules in subject with euvolemic hyponatremia. Clinicaltrials.gov. NCT00660959. Available from: http:// clinicaltrials.gov/ct2/show/NCT00660959
58. CardioKine, Inc. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of oral lixivaptan capsules in subjects with euvolemic hyponatremia. Clinicaltrials.gov. NCT00876798. Available from: http:// clinicaltrials.gov/ct2/show/NCT00876798
59. CardioKine, Inc. International, multicenter study of a twenty-eight week, open-label, titrated oral lixivaptan administration in patients with chronic hyponatremia: extension to studies CK-LX3401, 3405, and 3430. Clinicaltrials.gov. NCT01056848. Available from: http://clinicaltrials.gov/ ct2/show/NCT01056848
60. CardioKine, Inc. A study to define the ECG effects of lixivaptan compared to placebo and moxifloxacin in healthy adult men and women: a thorough EKG study. Clinicaltrials.gov. NCT00675701. Available from: http://clinicaltrials. gov/ ct2/show/NCT00675701
61. Naitoh M, Suzuki H, Murakami M, et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious in dogs. Am J Physiol 1994;267:H2245-54
62. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure, the EVEREST outcome trial. JAMA 2007;297:1319-31 (Pubitemid 46513233)
63. Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure, the EVEREST clinical status trials. JAMA 2007;297:1332-43 (Pubitemid 46513234)